S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.09 (+3.66%)
AAPL   250.93 (+1.29%)
FB   165.95 (+5.84%)
MSFT   150.67 (+0.65%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.44 (-1.03%)
NVDA   256.17 (+1.36%)
BABA   191.31 (+1.44%)
MU   44.52 (+2.39%)
GE   7.88 (+3.41%)
TSLA   501.65 (-2.47%)
AMD   47.18 (+1.29%)
T   30.26 (+1.41%)
ACB   0.89 (-13.62%)
F   5.08 (-2.12%)
NFLX   370.96 (+3.88%)
BAC   21.45 (-0.69%)
GILD   75.93 (+4.23%)
PRI   90.33 (+0.41%)
DIS   99.84 (+3.56%)
Log in

NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

$2.26
-0.02 (-0.88 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$2.15
Now: $2.27
$2.35
50-Day Range
$1.84
MA: $2.63
$3.06
52-Week Range
$1.74
Now: $2.27
$11.36
Volume549,238 shs
Average Volume1.90 million shs
Market Capitalization$260.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Read More
Spectrum Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$1.69 per share

Profitability

Net Income$-112,690,000.00

Miscellaneous

Employees235
Market Cap$260.02 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.


Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

How has Spectrum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPPI stock has decreased by 6.9% and is now trading at $2.2250. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Spectrum Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spectrum Pharmaceuticals.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Spectrum Pharmaceuticals.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Thursday, February, 27th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.02. The company's quarterly revenue was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) EPS. View Spectrum Pharmaceuticals' earnings history.

What price target have analysts set for SPPI?

4 Wall Street analysts have issued 1 year target prices for Spectrum Pharmaceuticals' stock. Their forecasts range from $4.00 to $19.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $10.50 in the next year. This suggests a possible upside of 371.9% from the stock's current price. View analysts' price targets for Spectrum Pharmaceuticals.

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News headlines about SPPI stock have been trending very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutSpectrum Pharmaceuticals.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 6,300,300 shares, a drop of 8.8% from the February 27th total of 6,910,000 shares. Based on an average daily volume of 1,812,700 shares, the days-to-cover ratio is currently 3.5 days. Currently, 6.2% of the company's stock are short sold. View Spectrum Pharmaceuticals' Current Options Chain.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Zynerba Pharmaceuticals (ZYNE), Progenics Pharmaceuticals (PGNX), Opko Health (OPK), TG Therapeutics (TGTX), Verastem (VSTM), Bausch Health Companies (BHC), AT&T (T) and Amicus Therapeutics (FOLD).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the following people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (4.29%), Renaissance Technologies LLC (2.48%), Macquarie Group Ltd. (2.42%), Norges Bank (2.15%), Geode Capital Management LLC (1.36%) and FMR LLC (1.23%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View institutional ownership trends for Spectrum Pharmaceuticals.

Which major investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, Macquarie Group Ltd., Sargent Investment Group LLC, Sargent Investment Group LLC, Panagora Asset Management Inc., Citigroup Inc., and UBS Group AG. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga, and William Ashton. View insider buying and selling activity for Spectrum Pharmaceuticals.

Which major investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, State Street Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Alpine Global Management LLC, Great West Life Assurance Co. Can, Nuveen Asset Management LLC, and Geode Capital Management LLC. View insider buying and selling activity for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $2.23.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $255.43 million and generates $109.33 million in revenue each year. The biotechnology company earns $-112,690,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe. View additional information about Spectrum Pharmaceuticals.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  806
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel